Zealand Pharma A/S is a biotechnology company that engages in the discovery, design and development of peptide based medicines. Its products include Soliqua and Lyxumia. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Soborg, Denmark.
Company profile
Ticker
ZLDPF, ZEAL
Exchange
Website
CEO
Emmanuel Dulac
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ZLDPF stock data
Latest filings (excl ownership)
15F-12B
Securities registration termination (foreign)
30 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Sep 22
25
Voluntary exchange delisting
20 Sep 22
6-K
Company announcement – No. 38 / 2022
7 Sep 22
6-K
Company announcement – No. 37 / 2022
31 Aug 22
6-K
Company Announcement – No. 36 / 2022
26 Aug 22
6-K
Current report (foreign)
10 Aug 22
6-K
Zealand Pharma launches long-term incentive program for Zealand’s Corporate Management and employees for 2022
2 Jun 22
S-8
Registration of securities for employees
25 May 22
Latest ownership filings
SC 13G/A
VAN HERK INVESTMENTS B.V.
14 Feb 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
3 Feb 21
SC 13G/A
VAN HERK INVESTMENTS B.V.
29 Jan 21
SC 13G/A
Zealand Pharma A/S
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
28 Jan 20
SC 13G/A
Zealand Pharma A/S
18 Sep 19
SC 13G/A
Zealand Pharma A/S
17 Sep 19
SC 13G/A
Zealand Pharma A/S
14 Feb 19
SC 13G/A
Zealand Pharma A/S
12 Feb 19
SC 13G
Zealand Pharma A/S
13 Jul 18
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2021
14.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 328.18 mm |
Total shares | 9.13 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Van Herk Investments B.V. | 7.24 mm | $260.15 mm |
Wellington Management | 1.89 mm | $68.03 mm |